Answers are grounded in this paper and cite their sources.
Background and aims. Liver biopsy is the gold standard fordiagnosis and staging of liver fibrosis, but it is invasive and hasmany complications that diminished its practice. Now, robust ofnon-invasive index for predicting fibrosis is very valuable. The aimof this study is to validate and determine the efficacy of noninvasivemarkers aspartate aminotransferase to platelet ratio(APRI), FIB4 and AFP versus Fibroscan for predicting the fibrosisstages of patients with chronic HCV infection. Methods: This crosssectionalstudy included 621 patients with chronic hepatitis Cinfection attended out-patient clinic (Medical center Beni-Suefbranch, the association of liver patient care, ELP, El-Mansoura)for HCV viral hepatitis treatment. The patients were diagnosedby RT-PCR. Sensitivity and specificity of APRI, FIb-4 and AFPwere estimated by receiver operator characteristic curve (ROC)for predicting stage of fibrosis versus Fibroscan. Results: Comparedto Fibroscan as standard at value 12 kPa, the sensitivity andspecificity of APRI was (67% and 61% and AUC= 0.747), ofFIb-4 was (77% and 72% and AUC = 0.769) and of AFP was (77%and 60% and AUC = 0.734) for predicting early stages of fibrosis(F0-F1-F2). However, with advanced liver fibrosis (F3-F4) comparedto Fibroscan at value 15 kPa, the sensitivity and specificity ofAPRI was (100% and 95.3% and AUC= 0.960) and of FIb-4was (100% and 87.4% and AUC= 0.879) and of AFP were(100% and 51% and AUC= 0.684) for predicting F4 fibrosis.Conclusion: Given the higher cost and reduced availability ofFibroscan, this study showed that, the non-invasive tests APRI,FIB-4 index and AFP are practically useful markers for diagnosisand monitoring of liver fibrosis among patients with chronicHCV patients especially with advanced liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Gamal et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: